CC
EVOK

Cornerstone Capital’s Evoke Pharma EVOK Stock Holding History

Cornerstone Capital’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-458
Closed -$33K – 93
2022
Q1 		$33K Buy
+458
New +$36.5K ﹤0.01% 91

Other funds holding EVOK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Cornerstone Capital's EVOK Position: Q2 2022 in Review

Cornerstone Capital sold out of Evoke Pharma (EVOK) in Q2 2022, closing a stake of 458 shares — an estimated $33K sold.

Cornerstone Capital first reported a position in EVOK in Q1 2022 and held it in 1 quarter. The position peaked at $33K in Q1 2022. 12 funds tracked by Wall St. Rank hold EVOK as of Q2 2022.

  • Cornerstone Capital reported no remaining Evoke Pharma position as of Q2 2022 after selling out during the quarter.
  • Cornerstone Capital sold 458 Evoke Pharma shares in Q2 2022, an estimated $33K.
  • Cornerstone Capital first reported a position in Evoke Pharma in Q1 2022 and held it in 1 quarter.
  • Cornerstone Capital's Evoke Pharma position peaked at $33K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2022.

Based on Cornerstone Capital's 13F filing for Q2 2022, filed 15 Aug 2022.